
RBN013209
CAS No. 2597933-17-8
RBN013209( —— )
Catalog No. M28545 CAS No. 2597933-17-8
RBN013209 is a potent CD38 inhibitor. RBN013209 is useful in the treatment of cancer.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 88 | Get Quote |
![]() ![]() |
5MG | 149 | Get Quote |
![]() ![]() |
10MG | 231 | Get Quote |
![]() ![]() |
25MG | 446 | Get Quote |
![]() ![]() |
50MG | 623 | Get Quote |
![]() ![]() |
100MG | 880 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameRBN013209
-
NoteResearch use only, not for human use.
-
Brief DescriptionRBN013209 is a potent CD38 inhibitor. RBN013209 is useful in the treatment of cancer.
-
DescriptionRBN013209 is a potent CD38 inhibitor. RBN013209 is useful in the treatment of cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorcPLA2α|Human Endogenous Metabolite
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2597933-17-8
-
Formula Weight384.43
-
Molecular FormulaC19H24N6O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (260.13 mM)
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Nakamura H, et al. Inhibition of arachidonic acid release and cytosolic phospholipase A2 alpha activity by D-erythro-sphingosine. Eur J Pharmacol. 2004 Jan 19;484(1):9-17.
molnova catalog



related products
-
D-fructose-1,6-dipho...
Fosfructose (Diphosphofructose;Esafosfan;FDP) is a cytoprotective natural sugar phosphate for the potential treatment of cardiovascular ischemia, sickle cell anemia and asthma.
-
FEMA 4774
FEMA 4774 is a positive allosteric modulator of T1R2/T1R3.?FEMA4774 shows obvious enhancement of the sweetness of sucrose in sensory evaluation tests.
-
mPEG-DSPE sodium
mPEG-DSPE sodium (DSPE-mPEG2000 sodium) is a PROTAC linker belonging to PEG and is involved in the synthesis of PROTAC molecules.